Caris Life Sciences (CAI) Operating Income (2024 - 2026)

Caris Life Sciences has reported Operating Income for 3 years, with the latest figure at $26.9 million in Q2 2026.

• On a quarterly basis, Operating Income rose 249.68% year-over-year to $26.9 million in Q2 2026; TTM through Jun 2026 was $153.3 million, a 188.17% increase from a year earlier, with the FY2025 full-year figure at $45.1 million, up 117.55% from the prior year.
• Operating Income was $26.9 million for Q2 2026 at Caris Life Sciences, up from $5.3 million in the prior quarter.
• The five-year high for Operating Income was $88.4 million in Q4 2025, with the low at -$67.0 million in Q2 2024.
• Average Operating Income over 3 years is -$9.7 million, with a median of -$18.0 million recorded in 2025.
• The largest YoY upside for Operating Income was 338.65% in 2025 against a maximum downside of 73.16% in 2025.
• Over 3 years, Operating Income stood at -$37.0 million in 2024, then jumped by 338.65% to $88.4 million in 2025, then slumped by 69.54% to $26.9 million in 2026.
• The last three Operating Income figures came in at $26.9 million (Q2 2026), $5.3 million (Q1 2026), and $88.4 million (Q4 2025), per Business Quant data.